| pubmed-article:11306850 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0221244 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0036508 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0022625 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C1704277 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0205467 | lld:lifeskim |
| pubmed-article:11306850 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:11306850 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11306850 | pubmed:dateCreated | 2001-4-18 | lld:pubmed |
| pubmed-article:11306850 | pubmed:abstractText | Ketoconazole (KET) is active to control dandruff and seborrhoeic dermatitis. Objective assessments comparing the 1% and 2% shampoo formulations are scant. This open, randomized parallel-group trial was carried out to differentiate the effectiveness of KET 1% and 2% in severe dandruff and seborrhoeic dermatitis. A total of 66 patients with severe dandruff or seborrhoeic dermatitis were randomized to each of the two groups. A 2-week run-in phase was followed by a 4-week treatment phase, in turn followed by a 4-week follow-up. The efficacy of treatments was evaluated by combining squamometry X, Malassezia spp. counts and clinical assessments. After 2 and 4 weeks of treatment, KET 2% was significantly superior over KET 1% (p < 0.001) for decreasing both in flakiness and Malassezia density from baseline. The same trend was observed in the mean change from baseline in the overall dandruff severity score. Only 6 mild adverse events were reported. During follow-up KET 2% showed a trend to fewer relapses than KET 1%. KET 2% had superior efficacy compared to KET 1% in the treatment of severe dandruff and scalp seborrhoeic dermatitis. Biometrological evaluations were correlated with the clinical improvements and therefore useful to incorporate in future dandruff studies. | lld:pubmed |
| pubmed-article:11306850 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11306850 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306850 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11306850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11306850 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11306850 | pubmed:issn | 1018-8665 | lld:pubmed |
| pubmed-article:11306850 | pubmed:author | pubmed-author:PiérardG EGE | lld:pubmed |
| pubmed-article:11306850 | pubmed:author | pubmed-author:Piérard-Franc... | lld:pubmed |
| pubmed-article:11306850 | pubmed:author | pubmed-author:De DonckerPP | lld:pubmed |
| pubmed-article:11306850 | pubmed:author | pubmed-author:ArreseJ EJE | lld:pubmed |
| pubmed-article:11306850 | pubmed:copyrightInfo | Copyright 2001 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:11306850 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11306850 | pubmed:volume | 202 | lld:pubmed |
| pubmed-article:11306850 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11306850 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11306850 | pubmed:pagination | 171-6 | lld:pubmed |
| pubmed-article:11306850 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:meshHeading | pubmed-meshheading:11306850... | lld:pubmed |
| pubmed-article:11306850 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11306850 | pubmed:articleTitle | Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. | lld:pubmed |
| pubmed-article:11306850 | pubmed:affiliation | Department of Dermatopathology, University of Liège, Belgium. | lld:pubmed |
| pubmed-article:11306850 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11306850 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11306850 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11306850 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11306850 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11306850 | lld:pubmed |
